| 8.4 0.35 (4.35%) | 10-24 15:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.01 | 1-year : | 12.36 |
| Resists | First : | 9.43 | Second : | 10.58 |
| Pivot price | 9.33 |
|||
| Supports | First : | 7.55 | Second : | 6.28 |
| MAs | MA(5) : | 8.63 |
MA(20) : | 9.21 |
| MA(100) : | 8.71 |
MA(250) : | 29.97 |
|
| MACD | MACD : | 0 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 8 |
D(3) : | 14 |
| RSI | RSI(14): 44.4  |
|||
| 52-week | High : | 114 | Low : | 0.09 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CNSP ] has closed above bottom band by 12.1%. Bollinger Bands are 17% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.57 - 8.65 | 8.65 - 8.7 |
| Low: | 7.88 - 7.98 | 7.98 - 8.05 |
| Close: | 7.93 - 8.1 | 8.1 - 8.2 |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Wed, 03 Sep 2025
Brain Cancer Drug Developer CNS Pharmaceuticals to Present Latest Advances at Major Investment Conference - Stock Titan
Fri, 15 Aug 2025
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance
Fri, 15 Aug 2025
Brain Cancer Breakthrough: CNS Pharma's TPI 287 Shows 52% Response Rate in Phase 1 GBM Trial - Stock Titan
Tue, 22 Jul 2025
CNS Pharmaceuticals Announces Reverse Stock Split - TipRanks
Fri, 18 Jul 2025
Brain Cancer Drug Developer CNS Pharmaceuticals Announces 1:12 Reverse Split to Maintain Nasdaq Listing - Stock Titan
Fri, 18 Jul 2025
CNS Pharmaceuticals Announces Reverse Stock Split - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 525990 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 64 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -114.7 % |
| Return on Equity (ttm) | -350.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.10405e+007 |
| Qtrly Earnings Growth | 131.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | 4.18 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.23 |
| Dividend | 0 |
| Forward Dividend | 41770 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|